Increased calcium release from the sarcoplasmic reticulum and greater calcium sensitivity in an Atrial Fibrillation heart can lead to intracellular calcium buildup and downregulation of L-type calcium channels. This shortens the action potential length and the refractory period, facilitating the conduction of re-entrant waves. Reduced atrial refractory time and wavelength can be caused by increased expression of inward-rectifier potassium ion channels. The arrhythmia is caused by the aberrant distribution of gap junction proteins such as GJA1 (also known as Connexin 43) and GJA5 (Connexin 40).
(AF) differs from atrial flutter (AFL), which occurs as an ordered electrical circuit in the right atrium. On an ECG, AFL produces typical saw-toothed F-waves with continuous amplitude and frequency, whereas Atrial Fibrillation does not. The discharges in the AFL flow swiftly across the atrium at a rate of 300 beats per minute (bpm). Except at sites where the local activation rate exceeds 500 bpm, there is no such regularity in Atrial Fibrillation.
While Atrial Fibrillation and atrial flutter are separate arrhythmias. While AF electrical impulses occur at a rapid rate, the majority of them do not result in a heartbeat. A heartbeat occurs when an electrical impulse from the atria travels to the ventricles through the atrioventricular (AV) node and causes them to contract.
If all atrioventricular impulses were to flow via the AV node during Atrial Fibrillation there would be significant ventricular tachycardia, resulting in a dramatic drop in cardiac output. The AV node prevents this perilous circumstance because its reduced conduction velocity slows the rate at which impulses reach the ventricles during Atrial Fibrillation.
Read More - https://cmilatestinsights.blogspot.com/2023/04/during-atrial-fibrillation-top-chambers.html
However, lack of well-trained physicians and the high cost of treatments are hampering the atrial fibrillation market growth.Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=1541The report has provided a detailed profile of some of the leading players in the global atrial fibrillation market such as Abbott Laboratories, Biosense Webster, Inc., Medtronic Plc, MicroPort Scientific Corporation, Boston Scientific Corporation, Biotronik SE & Co. KG, CardioFocus, Inc., AtriCure Inc., Koninklijke Philips N.V., and Osypka AG.
The market is also estimated to reach US$ 10,925.1 million revenue by the end of 2026.On the basis of product type, the EP ablation catheters are expected to emerge as the most preferred product in the global atrial fibrillation market.
On the basis of end-user, the market is segmented into electrophysiology labs, hospitals, and ambulatory surgical center.
A maximum number of catheter ablation are performed in Germany.Buy Atrial Fibrillation Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=1541=SRise in the Use of Less Invasive and Advanced Treatment for Atrial FibrillationMajor hospitals and medical centers are using a less invasive procedure known as catheter ablation for treating atrial fibrillation.
It also has facilitated quick recovery than the surgery.
A recent study by the researchers at the Klinikum Coburg and the University of Utah Health also showed that radiofrequency catheter ablation lowered mortality rates in patients suffering from atrial fibrillation.
